Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

All for one and one for all to fight flu.

Nabel GJ, Shiver JW.

Nature. 2019 Jan;565(7737):29-31. doi: 10.1038/d41586-018-07654-w. No abstract available.

PMID:
30573785
2.

A replication-defective human cytomegalovirus vaccine for prevention of congenital infection.

Wang D, Freed DC, He X, Li F, Tang A, Cox KS, Dubey SA, Cole S, Medi MB, Liu Y, Xu J, Zhang ZQ, Finnefrock AC, Song L, Espeseth AS, Shiver JW, Casimiro DR, Fu TM.

Sci Transl Med. 2016 Oct 26;8(362):362ra145.

PMID:
27797961
3.

Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.

Freed DC, Tang Q, Tang A, Li F, He X, Huang Z, Meng W, Xia L, Finnefrock AC, Durr E, Espeseth AS, Casimiro DR, Zhang N, Shiver JW, Wang D, An Z, Fu TM.

Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):E4997-5005. doi: 10.1073/pnas.1316517110. Epub 2013 Dec 2.

4.

Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines.

Koff WC, Russell ND, Walport M, Feinberg MB, Shiver JW, Karim SA, Walker BD, McGlynn MG, Nweneka CV, Nabel GJ.

Vaccine. 2013 Apr 18;31 Suppl 2:B204-8. doi: 10.1016/j.vaccine.2012.10.115. Review.

PMID:
23598483
5.

Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus.

Fu TM, Wang D, Freed DC, Tang A, Li F, He X, Cole S, Dubey S, Finnefrock AC, ter Meulen J, Shiver JW, Casimiro DR.

Vaccine. 2012 Dec 14;30(52):7469-74. doi: 10.1016/j.vaccine.2012.10.053. Epub 2012 Oct 26.

PMID:
23107592
6.

A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge.

Reynolds MR, Weiler AM, Piaskowski SM, Piatak M Jr, Robertson HT, Allison DB, Bett AJ, Casimiro DR, Shiver JW, Wilson NA, Lifson JD, Koff WC, Watkins DI.

Vaccine. 2012 Jun 22;30(30):4465-75. doi: 10.1016/j.vaccine.2012.04.082. Epub 2012 May 6.

7.

Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.

Qureshi H, Ma ZM, Huang Y, Hodge G, Thomas MA, DiPasquale J, DeSilva V, Fritts L, Bett AJ, Casimiro DR, Shiver JW, Robert-Guroff M, Robertson MN, McChesney MB, Gilbert PB, Miller CJ.

J Virol. 2012 Feb;86(4):2239-50. doi: 10.1128/JVI.06175-11. Epub 2011 Dec 7.

8.

Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study.

Li F, Finnefrock AC, Dubey SA, Korber BT, Szinger J, Cole S, McElrath MJ, Shiver JW, Casimiro DR, Corey L, Self SG.

PLoS One. 2011;6(6):e20479. doi: 10.1371/journal.pone.0020479. Epub 2011 Jun 10.

9.

Role of nonhuman primates in the evaluation of candidate AIDS vaccines: an industry perspective.

Staprans SI, Feinberg MB, Shiver JW, Casimiro DR.

Curr Opin HIV AIDS. 2010 Sep;5(5):377-85. doi: 10.1097/COH.0b013e32833d2e19. Review.

PMID:
20978377
10.

Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans.

Bett AJ, Dubey SA, Mehrotra DV, Guan L, Long R, Anderson K, Collins K, Gaunt C, Fernandez R, Cole S, Meschino S, Tang A, Sun X, Gurunathan S, Tartaglia J, Robertson MN, Shiver JW, Casimiro DR.

Vaccine. 2010 Nov 23;28(50):7881-9. doi: 10.1016/j.vaccine.2010.09.079. Epub 2010 Oct 23.

PMID:
20937317
11.

Clostridium difficile and methicillin-resistant Staphylococcus aureus: emerging concepts in vaccine development.

Kaslow DC, Shiver JW.

Annu Rev Med. 2011;62:201-15. doi: 10.1146/annurev-med-051109-101544. Review.

PMID:
20707676
12.

Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge.

Bommakanti G, Citron MP, Hepler RW, Callahan C, Heidecker GJ, Najar TA, Lu X, Joyce JG, Shiver JW, Casimiro DR, ter Meulen J, Liang X, Varadarajan R.

Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13701-6. doi: 10.1073/pnas.1007465107. Epub 2010 Jul 6.

13.

Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques.

Hirao LA, Wu L, Satishchandran A, Khan AS, Draghia-Akli R, Finnefrock AC, Bett AJ, Betts MR, Casimiro DR, Sardesai NY, Kim JJ, Shiver JW, Weiner DB.

Mol Ther. 2010 Aug;18(8):1568-76. doi: 10.1038/mt.2010.112. Epub 2010 Jun 15.

14.

Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates.

Bianchi E, Joyce JG, Miller MD, Finnefrock AC, Liang X, Finotto M, Ingallinella P, McKenna P, Citron M, Ottinger E, Hepler RW, Hrin R, Nahas D, Wu C, Montefiori D, Shiver JW, Pessi A, Kim PS.

Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10655-60. doi: 10.1073/pnas.1004261107. Epub 2010 May 18.

15.

Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge.

Casimiro DR, Cox K, Tang A, Sykes KJ, Feng M, Wang F, Bett A, Schleif WA, Liang X, Flynn J, Tobery TW, Wilson K, Finnefrock A, Huang L, Vitelli S, Lin J, Patel D, Davies ME, Heidecker GJ, Freed DC, Dubey S, O'Connor DH, Watkins DI, Zhang ZQ, Shiver JW.

J Virol. 2010 Mar;84(6):2996-3003. doi: 10.1128/JVI.00969-09. Epub 2009 Dec 30.

16.

Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens.

Asmuth DM, Brown EL, DiNubile MJ, Sun X, del Rio C, Harro C, Keefer MC, Kublin JG, Dubey SA, Kierstead LS, Casimiro DR, Shiver JW, Robertson MN, Quirk EK, Mehrotra DV.

J Infect Dis. 2010 Jan 1;201(1):132-41. doi: 10.1086/648591.

PMID:
19929694
17.

International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials.

Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, Mbewe B, Pitisuttithum P, Schechter M, Vardas E, Wolfe ND, Aste-Amezaga M, Casimiro DR, Coplan P, Straus WL, Shiver JW.

Vaccine. 2010 Jan 22;28(4):950-7. doi: 10.1016/j.vaccine.2009.10.145. Epub 2009 Nov 17.

PMID:
19925902
18.

Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.

O'Brien KL, Liu J, King SL, Sun YH, Schmitz JE, Lifton MA, Hutnick NA, Betts MR, Dubey SA, Goudsmit J, Shiver JW, Robertson MN, Casimiro DR, Barouch DH.

Nat Med. 2009 Aug;15(8):873-5. doi: 10.1038/nm.1991. Epub 2009 Jul 20.

19.

Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults.

Harro C, Sun X, Stek JE, Leavitt RY, Mehrotra DV, Wang F, Bett AJ, Casimiro DR, Shiver JW, DiNubile MJ, Quirk E; Merck V526-001 Study Group.

Clin Vaccine Immunol. 2009 Sep;16(9):1285-92. doi: 10.1128/CVI.00144-09. Epub 2009 Jul 15.

20.

Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge.

Wilson NA, Keele BF, Reed JS, Piaskowski SM, MacNair CE, Bett AJ, Liang X, Wang F, Thoryk E, Heidecker GJ, Citron MP, Huang L, Lin J, Vitelli S, Ahn CD, Kaizu M, Maness NJ, Reynolds MR, Friedrich TC, Loffredo JT, Rakasz EG, Erickson S, Allison DB, Piatak M Jr, Lifson JD, Shiver JW, Casimiro DR, Shaw GM, Hahn BH, Watkins DI.

J Virol. 2009 Jul;83(13):6508-21. doi: 10.1128/JVI.00272-09. Epub 2009 Apr 29.

21.

Synthetic peptide vaccines: the quest to develop peptide vaccines for influenza, HIV and Alzheimer's disease.

Bianchi E, Ingallinella P, Finotto M, Joyce J, Liang X, Miller MD, Kinney GG, Ciliberto G, Shiver JW, Pessi A.

Adv Exp Med Biol. 2009;611:121-3. No abstract available.

PMID:
19400121
22.

Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys.

Fu TM, Grimm KM, Citron MP, Freed DC, Fan J, Keller PM, Shiver JW, Liang X, Joyce JG.

Vaccine. 2009 Feb 25;27(9):1440-7. doi: 10.1016/j.vaccine.2008.12.034. Epub 2009 Jan 13.

PMID:
19146898
23.

PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination.

Finnefrock AC, Tang A, Li F, Freed DC, Feng M, Cox KS, Sykes KJ, Guare JP, Miller MD, Olsen DB, Hazuda DJ, Shiver JW, Casimiro DR, Fu TM.

J Immunol. 2009 Jan 15;182(2):980-7.

24.

Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.

Harro CD, Robertson MN, Lally MA, O'Neill LD, Edupuganti S, Goepfert PA, Mulligan MJ, Priddy FH, Dubey SA, Kierstead LS, Sun X, Casimiro DR, DiNubile MJ, Shiver JW, Leavitt RY, Mehrotra DV; Merck V520-007/012 Study Teams.

AIDS Res Hum Retroviruses. 2009 Jan;25(1):103-14. doi: 10.1089/aid.2008.0212.

25.

Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus.

Fu TM, Freed DC, Horton MS, Fan J, Citron MP, Joyce JG, Garsky VM, Casimiro DR, Zhao Q, Shiver JW, Liang X.

Virology. 2009 Mar 1;385(1):218-26. doi: 10.1016/j.virol.2008.11.035. Epub 2008 Dec 13.

26.

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR; Step Study Protocol Team.

Lancet. 2008 Nov 29;372(9653):1894-1905. doi: 10.1016/S0140-6736(08)61592-5. Epub 2008 Nov 13.

27.

An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions.

Joyce JG, Krauss IJ, Song HC, Opalka DW, Grimm KM, Nahas DD, Esser MT, Hrin R, Feng M, Dudkin VY, Chastain M, Shiver JW, Danishefsky SJ.

Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15684-9. doi: 10.1073/pnas.0807837105. Epub 2008 Oct 6.

28.

Estimating the impact of vaccination on acute simian-human immunodeficiency virus/simian immunodeficiency virus infections.

Petravic J, Ribeiro RM, Casimiro DR, Mattapallil JJ, Roederer M, Shiver JW, Davenport MP.

J Virol. 2008 Dec;82(23):11589-98. doi: 10.1128/JVI.01596-08. Epub 2008 Sep 17.

29.

The effect of early versus delayed challenge after vaccination in controlling SHIV 89.6P infection.

Chavez LL, Davenport MP, Shiver JW, Tussey LG, Cox KS, Bachinsky M, Wang F, Huang L, Schleif WA, Davies ME, Tang A, Casimiro DR, Perelson AS, Ribeiro RM.

Virology. 2008 Nov 10;381(1):75-80. doi: 10.1016/j.virol.2008.07.042. Epub 2008 Sep 14.

30.

DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles.

Cox KS, Clair JH, Prokop MT, Sykes KJ, Dubey SA, Shiver JW, Robertson MN, Casimiro DR.

J Virol. 2008 Aug;82(16):8161-71. doi: 10.1128/JVI.00620-08. Epub 2008 Jun 4.

31.

Enhanced in vivo transgene expression and immunogenicity from plasmid vectors following electrostimulation in rodents and primates.

Simon AJ, Casimiro DR, Finnefrock AC, Davies ME, Tang A, Chen M, Chastain M, Kath GS, Chen L, Shiver JW.

Vaccine. 2008 Sep 19;26(40):5202-9. doi: 10.1016/j.vaccine.2008.03.058. Epub 2008 Apr 14.

PMID:
18472195
32.

Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.

Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, DiNubile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E; Merck V520-016 Study Group.

Clin Infect Dis. 2008 Jun 1;46(11):1769-81. doi: 10.1086/587993.

PMID:
18433307
33.

Primary human immunodeficiency virus type 1 (HIV-1) infection during HIV-1 Gag vaccination.

Balamurugan A, Lewis MJ, Kitchen CM, Robertson MN, Shiver JW, Daar ES, Pitt J, Ali A, Ng HL, Currier JS, Yang OO.

J Virol. 2008 Mar;82(6):2784-91. doi: 10.1128/JVI.01720-07. Epub 2008 Jan 16.

34.

HIV type 1 vaccines for worldwide use: predicting in-clade and cross-clade breadth of immune responses.

Finnefrock AC, Liu X, Opalka DW, Shiver JW, Casimiro DR, Condra JH.

AIDS Res Hum Retroviruses. 2007 Oct;23(10):1283-92.

PMID:
17961117
35.

Fully synthetic carbohydrate HIV antigens designed on the logic of the 2G12 antibody.

Krauss IJ, Joyce JG, Finnefrock AC, Song HC, Dudkin VY, Geng X, Warren JD, Chastain M, Shiver JW, Danishefsky SJ.

J Am Chem Soc. 2007 Sep 12;129(36):11042-4. Epub 2007 Aug 21. No abstract available.

PMID:
17711286
36.

Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay.

Dubey S, Clair J, Fu TM, Guan L, Long R, Mogg R, Anderson K, Collins KB, Gaunt C, Fernandez VR, Zhu L, Kierstead L, Thaler S, Gupta SB, Straus W, Mehrotra D, Tobery TW, Casimiro DR, Shiver JW.

J Acquir Immune Defic Syndr. 2007 May 1;45(1):20-7.

PMID:
17310936
37.

Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC.

Kierstead LS, Dubey S, Meyer B, Tobery TW, Mogg R, Fernandez VR, Long R, Guan L, Gaunt C, Collins K, Sykes KJ, Mehrotra DV, Chirmule N, Shiver JW, Casimiro DR.

AIDS Res Hum Retroviruses. 2007 Jan;23(1):86-92.

PMID:
17263637
38.

Evaluation of cellular immune responses in subjects chronically infected with HIV type 1.

Fu TM, Dubey SA, Mehrotra DV, Freed DC, Trigona WL, Adams-Muhler L, Clair JH, Evans TG, Steigbigel R, Jacobson JM, Goepfert PA, Mulligan MJ, Kalams SA, Rinaldo C, Zhu L, Cox KS, Guan L, Long R, Persaud N, Caulfield MJ, Sadoff JC, Emini EA, Thaler S, Shiver JW.

AIDS Res Hum Retroviruses. 2007 Jan;23(1):67-76.

PMID:
17263635
39.

Early depletion of proliferating B cells of germinal center in rapidly progressive simian immunodeficiency virus infection.

Zhang ZQ, Casimiro DR, Schleif WA, Chen M, Citron M, Davies ME, Burns J, Liang X, Fu TM, Handt L, Emini EA, Shiver JW.

Virology. 2007 May 10;361(2):455-64. Epub 2007 Jan 16.

40.

A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjects.

Tobery TW, Dubey SA, Anderson K, Freed DC, Cox KS, Lin J, Prokop MT, Sykes KJ, Mogg R, Mehrotra DV, Fu TM, Casimiro DR, Shiver JW.

AIDS Res Hum Retroviruses. 2006 Nov;22(11):1081-90.

PMID:
17147493
41.

Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon.

Gupta SB, Mast CT, Wolfe ND, Novitsky V, Dubey SA, Kallas EG, Schechter M, Mbewe B, Vardas E, Pitisuttithum P, Burke D, Freed D, Mogg R, Coplan PM, Condra JH, Long RS, Anderson K, Casimiro DR, Shiver JW, Straus WL.

J Acquir Immune Defic Syndr. 2006 Jun;42(2):135-9.

PMID:
16760794
42.

Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239.

Wilson NA, Reed J, Napoe GS, Piaskowski S, Szymanski A, Furlott J, Gonzalez EJ, Yant LJ, Maness NJ, May GE, Soma T, Reynolds MR, Rakasz E, Rudersdorf R, McDermott AB, O'Connor DH, Friedrich TC, Allison DB, Patki A, Picker LJ, Burton DR, Lin J, Huang L, Patel D, Heindecker G, Fan J, Citron M, Horton M, Wang F, Liang X, Shiver JW, Casimiro DR, Watkins DI.

J Virol. 2006 Jun;80(12):5875-85.

43.

Influence of peak viral load on the extent of CD4+ T-cell depletion in simian HIV infection.

Davenport MP, Zhang L, Shiver JW, Casmiro DR, Ribeiro RM, Perelson AS.

J Acquir Immune Defic Syndr. 2006 Mar;41(3):259-65.

PMID:
16540926
44.

Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaques.

McDermott AB, O'Connor DH, Fuenger S, Piaskowski S, Martin S, Loffredo J, Reynolds M, Reed J, Furlott J, Jacoby T, Riek C, Dodds E, Krebs K, Davies ME, Schleif WA, Casimiro DR, Shiver JW, Watkins DI.

J Virol. 2005 Dec;79(24):15556-66.

45.

Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag.

Casimiro DR, Wang F, Schleif WA, Liang X, Zhang ZQ, Tobery TW, Davies ME, McDermott AB, O'Connor DH, Fridman A, Bagchi A, Tussey LG, Bett AJ, Finnefrock AC, Fu TM, Tang A, Wilson KA, Chen M, Perry HC, Heidecker GJ, Freed DC, Carella A, Punt KS, Sykes KJ, Huang L, Ausensi VI, Bachinsky M, Sadasivan-Nair U, Watkins DI, Emini EA, Shiver JW.

J Virol. 2005 Dec;79(24):15547-55.

46.

A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.

Miller MD, Geleziunas R, Bianchi E, Lennard S, Hrin R, Zhang H, Lu M, An Z, Ingallinella P, Finotto M, Mattu M, Finnefrock AC, Bramhill D, Cook J, Eckert DM, Hampton R, Patel M, Jarantow S, Joyce J, Ciliberto G, Cortese R, Lu P, Strohl W, Schleif W, McElhaugh M, Lane S, Lloyd C, Lowe D, Osbourn J, Vaughan T, Emini E, Barbato G, Kim PS, Hazuda DJ, Shiver JW, Pessi A.

Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14759-64. Epub 2005 Oct 3.

47.

Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.

Liang X, Casimiro DR, Schleif WA, Wang F, Davies ME, Zhang ZQ, Fu TM, Finnefrock AC, Handt L, Citron MP, Heidecker G, Tang A, Chen M, Wilson KA, Gabryelski L, McElhaugh M, Carella A, Moyer C, Huang L, Vitelli S, Patel D, Lin J, Emini EA, Shiver JW.

J Virol. 2005 Oct;79(19):12321-31.

48.

Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation.

Geels MJ, Dubey SA, Anderson K, Baan E, Bakker M, Pollakis G, Paxton WA, Shiver JW, Goudsmit J.

J Virol. 2005 Sep;79(17):11247-58.

49.

High-potency human immunodeficiency virus vaccination leads to delayed and reduced CD8+ T-cell expansion but improved virus control.

Davenport MP, Zhang L, Bagchi A, Fridman A, Fu TM, Schleif W, Shiver JW, Ribeiro RM, Perelson AS.

J Virol. 2005 Aug;79(15):10059-62.

50.

Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor.

Bianchi E, Liang X, Ingallinella P, Finotto M, Chastain MA, Fan J, Fu TM, Song HC, Horton MS, Freed DC, Manger W, Wen E, Shi L, Ionescu R, Price C, Wenger M, Emini EA, Cortese R, Ciliberto G, Shiver JW, Pessi A.

J Virol. 2005 Jun;79(12):7380-8.

Supplemental Content

Loading ...
Support Center